Product Images Afinitor

This is a statistical report on the probability of a hazard ratio with corresponding confidence intervals, p-value, and Kaplan-Meier medians based on a clinical trial comparing the effectiveness of Afinitor and Placebo. The data shows that Afinitor had a significantly longer duration of survival compared to Placebo. The data also includes a graph of the censoring times for both treatment groups over time.*

This text provides information on the results of a study or experiment. It includes percentages and hazard ratio with confidence intervals. The logrank p-value is also given. There are two treatments compared: Afinitor and Placebo. The Kaplan-Meier medians are shown for both treatments in terms of months. Additionally, censoring times are provided for both treatments. The time (in months) is listed at the end.*

This is a description of a box of 28 tablets of Afinitor (everolimus) made by Novartis. The box is labeled with the drug's name and information including contact information for more information. The tablets are only available by prescription. The also included some irregular characters, so the description is not exact, but it reflects what's clear from the text.*

This appears to be a description of several tablets containing everolimus, marketed under the brand names AFINITOR and BARCINATOR, in 28-tablet blister cards. The NDC code for the AFINITOR tablets is 0078056651, and their manufacturer is Novartis. The text also provides a phone number and website for obtaining more information about the tablets.*

This text appears to be from a medication package of AFINITOR tablets, which contain 10mg of everolimus. The package contains 28 tablets and is only available with a prescription. The manufacturer of the medication is Novartis. More information about the medication is available by visiting www.AFINTOR.com or contacting a toll-free number.*

AFINITOR is a medication contained in a box of 28 tablets with a NDC number of 0078062051. Each tablet contains everolimus and is Rx-only. For more information about AFINITOR, visit their website or call their hotline.*

The text provides information on the progression-free survival probability of two different treatments, Everolimus 10mg - exemestane, and Placebo-exemestane. The Kaplan-Meier medians indicate that Everolimus has a median progression-free survival probability of 7.8 months while the Placebo-exemestane treatment has a median progression-free survival probability of 32 months. The log-rank p-value is <0001 and there were four censoring times. The text also includes a graph representing the progression-free survival probability over time (in months) for both treatments.*

This appears to be a medication information leaflet for AFINITOR DISPERZ - a brand of everolimus tablets for oral suspension used for treating certain types of cancer. The text mentions the dosage (2mg), and instructions cautioning against swallowing the tablets whole, chewing, or crushing them.*

AFINITOR DISPERZ is a medication that comes in tablet form containing everolimus and is available in a strength of 3mg. The tablets must not be swallowed whole, chewed or crushed. They must be dispersed in water before consumption. The provided text seems to be a warning or instruction for proper medication intake.*

This is a description of medication called AFINITOR DISPERZ (everolimus tablets for oral suspension) available in 5mg strength. The tablets should not be swallowed whole or chewed. They must be dispersed in water before taking. There are additional details about the product that are not available in the provided text.*

This appears to be a graph displaying the probability of an event over time (in months) for two groups of patients - one group on Everolimus + BSC and the other on Placebo + BSC. The number of patients at risk for each group is also shown over time.*